Pharmacokinetics, pharmacodynamics, metabolism, toxicology and residues of phenylbutazone in humans and horses.

This research review seeks to evaluate the safety of the presence of phenylbutazone, a non-steroidal anti-inflammatory drug, in horse meat intended for human consumption. Based on analysis of drug’s toxicity, pharmacokinetic and pharmacodynamic properties, the study concludes that trace residuals of phenylbutazone in horse meat do not pose a public health risk.

Pharmacokinetics and Pharmacodynamics of Phenylbutazone

• The review conducts a thorough analysis of the pharmacokinetic and pharmacodynamic behavior of phenylbutazone in both humans and horses. These two aspects are crucial because they will determine how the drug is absorbed, distributed, metabolized and excreted in the body as well as the relationship between the dose and its therapeutic effect.

Metabolic and Toxicological Profiles of Phenylbutazone

• Additionally, the review investigates the metabolic process of phenylbutazone. This helps understand how the drug is converted within the body and it helps predict its potential interactions with other substances.
• The article scrutinizes the toxicological attributes of phenylbutazone. This refers to the potential harm it can cause to the body, including potential life-threatening blood disorders that have been associated with phenylbutazone therapy in humans.

Toxicity Data in Laboratory Animals

• The review also evaluates the toxicity data from laboratory animals to understand the potential risks that the drug might post when present in horse meat consumed by humans.

Phenylbutazone Residues in Food Producing Species

• This section investigates the presence of phenylbutazone residues in various species that are intended for human consumption, beyond horses. This part is important to assess the wider implications of the drug’s presence in our food chain.

Potential Hazard of Phenylbutazone Consumption via Horse Meat

• The study provides a preliminary assessment of the potential hazard associated with the consumption of horse meat containing phenylbutazone and its metabolites. The study concludes that considering phenylbutazone is not classified as a carcinogenic substance in humans, and noting that blood dyscrasias in humans are likely to be dose and treatment duration-dependent, the illegal and erratic appearance of trace amount residues of phenylbutazone in horse meat is not a public health issue.